• Rhythm Pharmaceuticals launched IMCIVREE in Japan for acquired hypothalamic obesity following listing on the National Health Insurance drug price list.
• Market entry follows MHLW clearance in August, supported by Phase 3 TRANSCEND data showing an 18.8% placebo-adjusted BMI reduction.
• Rhythm estimates 5,000 to 8,000 people in Japan live with acquired hypothalamic obesity, creating a new commercial market for the drug.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhythm Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610131930PRIMZONEFULLFEED9844642) on October 13, 2026, and is solely responsible for the information contained therein.